Myotonic dystrophy type 1 (DM1) is an inherited neuromuscular disease which results from an 21 expansion of repetitive DNA elements within the 3' untranslated region of the DMPK gene. Some 22 patients develop multiple pilomatricomas as well as malignant tumors in other tissues. Mutations of the 23 catenin-β gene (CTNNB1) could be demonstrated in most non-syndromic pilomatricomas.
Introduction 76
Myotonic dystrophy type 1 (DM1, OMIM 160900) is an inherited and the most common neuromuscular 77 disorder characterized genetically by an expansion of trinucleotide repeats within the 3' untranslated 78 region of the DMPK (DM1 protein kinase) gene [1] [2] [3] [4] [5] . The DNA-expansion within the DMPK gene is 79 considered causative for the observed muscle weakness and cardiac disease [5, 6] . Besides, affected 80 patients develop early cataract as well as insulin resistance and cognitive impairment.
81
Although initially hypothesized that DM1 is primarily caused by mutations that generate an 82 amplification of CTG repeats [1] , the underlying mutation driving this amplification has not been 83 identified yet. It has, nevertheless, been speculated that the DNA mismatch-repair mechanism as well 84 as mechanisms involved in the resolution of secondary DNA structures such as hairpins or R-loops 85 might be implicated in some form [7] [8] [9] . In order to explain the multiple non-muscular clinical symptoms 86 which are associated which DM1, an alternative gain-of-function-RNA hypothesis was formulated and 87 subsequently proven. It could be demonstrated that expanded CTG-repeats within the DMPK gene are 88 transcribed into RNA and that this non-translated repetitive RNA then forms aggregates with various 89 splicing regulators, which in turn impair transcription of multiple genes in various tissues and which 90 might also be responsible for further expansion of CTG-repeats [5, [10] [11] [12] .
91
For more than 50 years it has been known that patients with myotonic dystrophy may develop multiple 92 pilomatricomas (synonyms: pilomatrixoma, calcifying epithelioma of Malherbe) which are benign 93 calcifying skin tumors deriving from hair matrix cells [13] [14] [15] . Pilomatricoma is a relatively rare tumor 94 but it represents the second most frequent skin tumor in childhood. Age distribution seems to follow a 95 bimodal distribution with a first marked peak in the first decennium and a second small and broad 96 increase in prevalence between 41-and 71-years of age. Non-syndromic pilomatricoma occurs mostly 97 as a solitary lesion in the head and neck region. While the scalp is affected in childhood in only 98 approx. 4%, pilomatricomas of the scalp are more frequent in adulthood (approx. 27%) [16] [17] [18] , 99 whereas in myotonic dystrophy, most pilomatricomas are located on the scalp [15] . In contrast to non-100 syndromic pilomatricoma, myotonic dystrophy-associated pilomatricoma is a disease of adulthood.
101
The overall frequency of pilomatricoma in DM1 seems to be lower than 10% with a male 102 predominance [19] [20] [21] [22] .
103
Multiple pilomatricomas have also been encountered in patients with Turner syndrome, Rubinstein-
104
Taybi syndrome, trisomy 9, Gardner syndrome and in patients with constitutive mismatch repair 105 deficiency (CMMR-D) [23] . A family with non-syndromic multiple pilomatricomas has been described 106 as well [24] . Mutations of the catenin-β gene (CTNNB1) have been found in many analyzed non-107 syndromic pilomatricomas as well as in pilomatricomas associated with constitutive mismatch repair 108 deficiency and in pilomatrical carcinomas [23, [25] [26] [27] [28] [29] . Pilomatricomas have been described in a few 109 patients with APC-mutated familial adenomatous polyposis (Gardener syndrome) but APC-mutations 110 have not been reported in non-syndromic pilomatricoma [25, 30] . The WNT/APC/β-catenin pathway 5 111 regulates hair follicle development, hair follicle cycling, and hair growth and β-catenin is strongly 112 expressed in the proliferating matrix cells of pilomatricoma, both in catenin-β mutated tumors and in 113 pilomatricomas without a CTNNB1 mutation [28] . Therefore, mutation of the CTNNB1 most likely 114 represents the tumor driving oncogenic event in pilomatricoma.
115
Besides benign pilomatricomas, patients with DM1 also have an enhanced risk of malignant tumors.
116
The cancer risk is elevated by a factor of approx. 1.8 [31] ; the most prevalent cancers affect skin, 117 thyroid, ovary, and breast [15] . The relative cancer risk is elevated especially for testicular cancer in 118 men, endometrial cancer and ovary cancer in women as well as brain cancer, thyroid cancer and Non-
119
Hodgkin's lymphoma in both sexes [15, 20, 31, 32] .
120
Several hypotheses have been forwarded or can be formulated in order to explain the susceptibility to 121 pilomatricoma and cancer in myotonic dystrophy patients: 
Results

148
Analysis of CTG repeat expansions 149
The patient demonstrated one DMPK allele in the normal range with 5 +/-2 repeats as well as an 150 expanded DMPK allele with more than 400 CTG-repeats.
152
Catenin-beta 1 gene sequencing 153 We analyzed the Catenin beta 1 gene (CTNNB1) for mutations in six samples from four benign 154 pilomatricomas, and in one sample of a pilomatrical carcinoma obtained from the patient ( Fig 1A-E ). In 155 all samples we could detect mutations at typical hotspot regions of exon 3 of CTNNB1 (Table 1) .
156
Two pilomatricomas and one pilomatrical carcinoma demonstrated mutations which targeted codon 33 157 (S33C, S33F, S33C). One pilomatricoma demonstrating a hitherto non described small duplication 158 within codons 33 and 34 (c.99_101dup, p.G34dup.). Another larger pilomatricoma which was 159 microdissected at two areas demonstrated clonal heterogeneity as one area only demonstrated a 160 mutation at codon 41 (T41I) while the other tissue area only displayed a mutation at codon 34 (G34V). 
161
214
The detection of different somatic CTNNB mutations in different pilomatricomas and in the pilomatrical 215 carcinoma as well as the fact that the patient developed 10 pilomatricomas and one pilomatrical 216 carcinoma within 4 years, strongly suggests that the patient displays a hypermutation phenotype. The
217
distribution of mutations detected in the tumors of the patient seems to differ slightly from the mutation 218 distribution displayed by non-syndromic pilomatricomas and pilomatrical carcinomas as no mutations 9 219 were found in codon 37; however, the number of sequenced tumors in the patient is too low for any 220 statistical proof (Table 1) .
221
The degree of genetic instability present in DM1 patients most likely varies considerably. 
233
In order to detect additional gene mutations which might modify genetic instability we performed NGS 234 analysis on 161 cancer-related genes with tumor material of the pilomatricoma with the G34 235 duplication and of the pilomatrical carcinoma and compared the result with the patient's blood.
236
The only additional mutation which could be detected by NGS was the heterozygous germline patients with DM1 and pilomatricomas should be screened for defects in cancer-driving genes.
248
Although the molecular mechanisms responsible for the hypermutation phenotype remain unexplained 249 in the described patient, the multiple occurrence of pilomatricomas with individual somatic CTNNB1 250 mutations suggests some characteristics of the putative genetic defect:
251
The CTNNB1 gene as well as the hair matrix cells seem to be preferentially targeted by the unknown 252 genetic defect as pilomatricoma is a rare benign neoplasm and other potential CTNNB1 driven 253 neoplasms do not seem to be more frequent in DM1 patients with the exception of endometrial cancer.
254
According to the COSMIC database, CTNNB1 mutations have been detected at more than 10% 255 frequency in neoplasms of pituitary (37%), soft tissue (36%), liver (22%), endometrium (18%), adrenal 256 gland 13% and small intestine 12% (only entries with more than 100 sequenced samples): 
271
The observation that multiple pilomatricomas with CTNNB1 mutations have been observed in patients 272 with constitutive mismatch repair deficiency (CMMR-D) associated with PMS2 germline mutations [22] 273 and that CTNNB1 mutations are frequent in colon cancers of HNPCC patients with MLH1 repeats is linked to overexpression of the mismatch repair proteins MSH2, MSH3 or PMS2 [7, 9, 36] .
282
DNA mismatch repair proteins do not only play a role in post replication DNA mismatch repair but also 283 seem to be implicated in double strand break repair, transcription-coupled repair and nucleotide 
